Quantum Biopharma Class B Subordinate Voting Shares
QNTM
26 hedge funds and large institutions have $1.5M invested in Quantum Biopharma Class B Subordinate Voting Shares in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
22% more capital invested
Capital invested by funds: $1.23M → $1.5M (+$275K)
4.21% more ownership
Funds ownership: 6.66% → 10.87% (+4.2%)
4% more funds holding
Funds holding: 25 → 26 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$448K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$124K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$111K |
| 4 |
Jane Street
New York
|
+$79.6K |
| 5 |
NS
NBC Securities
Birmingham,
Alabama
|
+$33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$59K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$378 |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$343 |
| 4 |
Mariner
Overland Park,
Kansas
|
-$278 |
| 5 |
MG
Marex Group
London,
|
-$151 |
QNTM Hedge Fund Activity: Q2 2026 in Review
26 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q2 2026, worth a combined $1.5M — up 22% from $1.23M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new QNTM positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 4 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $448K. The largest seller was Virtu Financial, exiting entirely with an estimated $59K sold.
- 26 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q2 2026, up from 25 in Q1 2026.
- Funds reported $1.5M of Quantum Biopharma Class B Subordinate Voting Shares stock for Q2 2026, up 22% quarter-over-quarter.
- 4 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q2 2026 and 3 closed out, a net change of +1 holder.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q2 2026 was AdvisorShares Investments, an estimated $448K added.
- The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q2 2026 was Virtu Financial, an estimated $59K sold.
Based on aggregated 13F filings for Q2 2026.